Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 TrialDaiichi Sankyo2023-09-14 09:55:03ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung
-
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b TrialDaiichi Sankyo2023-09-14 09:48:35Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small
-
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trialDaiichi Sankyo2023-06-05 14:38:53Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small
-
ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid TumorsDaiichi Sankyo2023-06-08 21:19:11ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing
-
Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHADaiichi Sankyo2023-06-05 14:44:25Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with
-
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2023-01-31 12:28:25ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast
-
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2023-01-04 14:32:17ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2022-12-19 14:32:49ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer
-
ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric CancerDaiichi Sankyo2022-12-19 14:33:43ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
-
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early TrialsDaiichi Sankyo2022-12-09 10:52:07Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in
